Journal article · 2017 · Open access
Regulatory considerations on endpoints in ovarian cancer drug development
Cancer, 123(14), 2604–2608 · Published 12 May 2017 · DOI 10.1002/cncr.30652
In brief
“Regulatory considerations on endpoints in ovarian cancer drug development” is a 2017 journal article by Sanjeeve Balasubramaniam and 3 co-authors, published in Cancer. OpenAlex counts 6 citations as of 22 November 2026. It is open access: the full text is free to read at Cancer.
- Citations
- 6
- Most cited in
- 2017 (2)
- Field-weighted impact
- 0.61
- References
- 13
- Authors
- 4
Abstract
Ovarian cancer remains a disease entity that is responsible for considerable morbidity and mortality among women worldwide. Modern drug research pipelines and accelerated drug development timelines applied to other disease entities have begun to make an impact on treatment options for patients with advanced ovarian cancer, as exemplified by the recent accelerated approval of 2 agents for this disease as the forerunners of a growing number of registrational trials. Regulatory flexibility for this serious and life-threatening condition spurs the consideration of intermediate endpoints for regulatory trial design, including potential applications in the development of newer therapeutic classes such as targeted therapies and immunotherapies for patients with advanced ovarian cancer. Cancer 2017;123:2604-8. © 2017 American Cancer Society.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Balasubramaniam, S., Kim, G. S., McKee, A. E., & Pazdur, R. (2017). Regulatory considerations on endpoints in ovarian cancer drug development. Cancer, 123(14), 2604–2608. https://doi.org/10.1002/cncr.30652
MLA 9
Balasubramaniam, Sanjeeve, et al. “Regulatory considerations on endpoints in ovarian cancer drug development.” Cancer, vol. 123, no. 14, 2017, pp. 2604–2608. https://doi.org/10.1002/cncr.30652.
Chicago
Balasubramaniam, Sanjeeve, Geoffrey S. Kim, Amy E. McKee, and Richard Pazdur. 2017. “Regulatory considerations on endpoints in ovarian cancer drug development.” Cancer 123 (14): 2604–2608. https://doi.org/10.1002/cncr.30652.
Harvard
Balasubramaniam, S. et al. (2017) ‘Regulatory considerations on endpoints in ovarian cancer drug development’, Cancer, 123(14), pp. 2604–2608. doi:10.1002/cncr.30652.
IEEE
S. Balasubramaniam, G. S. Kim, A. E. McKee, and R. Pazdur, “Regulatory considerations on endpoints in ovarian cancer drug development,” Cancer, vol. 123, no. 14, pp. 2604–2608, 2017, doi: 10.1002/cncr.30652.
BibTeX
@article{balasubramaniam2017regulatory,
title = {{Regulatory considerations on endpoints in ovarian cancer drug development}},
author = {Balasubramaniam, Sanjeeve and Kim, Geoffrey S. and McKee, Amy E. and Pazdur, Richard},
journal = {Cancer},
year = {2017},
volume = {123},
number = {14},
pages = {2604--2608},
doi = {10.1002/cncr.30652},
url = {https://doi.org/10.1002/cncr.30652}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2017 | 2 | |
| 2018 | 2 | |
| 2020 | 1 | |
| 2026 | 1 |
Its field-weighted citation impact is 0.61: it has been cited 0.61 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- ovarian cancer
- drug development
- regulatory endpoints
- intermediate endpoints
- accelerated approval
- targeted therapy
- immunotherapy
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Balasubramaniam, S., Kim, G. S., McKee, A. E., & Pazdur, R. (2017). Regulatory considerations on endpoints in ovarian cancer drug development. Cancer, 123(14), 2604–2608. https://doi.org/10.1002/cncr.30652
How many times has this paper been cited?
6 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Cancer: sign in and open the PDF from this page.
Who wrote this paper?
Sanjeeve Balasubramaniam, Geoffrey S. Kim, Amy E. McKee, Richard Pazdur.
What is the DOI of this paper?
10.1002/cncr.30652, permanently at https://doi.org/10.1002/cncr.30652. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.